GILD vs GOSS · P/E 18, rev $7.80B vs rev $26.2M
Gilead Sciences Inc (GILD) versus Gossamer Bio Inc (GOSS) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Gossamer Bio Inc (GOSS) is a biotechnology company listed on US.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported GOSS revenue for 2026-06-30 was $26.2M. Net income was -$29.8M. Revenue was up 54.5% from 2026-03-31 to 2026-06-30. GOSS currently screens at market cap $47.0M.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. GOSS currently screens at market cap $47.0M.
Not investment advice. Open the GILD and GOSS stock pages for the full models.
Not investment advice.